World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
80
Citations
26905
World Ranking
17001
National Ranking
1545

Mark R. Middleton publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Mark R. Middleton sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 402 publications — 39th percentile

39% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Mark R. Middleton D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Mark R. Middleton sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 80 D-Index — 16th percentile

16% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Mark R. Middleton is affiliated with the University of Oxford in the United Kingdom. Their research spans a broad range of topics primarily within the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a particular focus on oncology and related subfields.

The main fields of study covered by their work include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these areas, their subfields of study comprise:

  • Oncology
  • Immunology
  • Molecular Biology
  • Genetics
  • Cancer Research

The research topics most frequently addressed include:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Melanoma and MAPK Pathways
  • Cancer Genomics and Diagnostics
  • Virus-based gene therapy research
  • Cutaneous Melanoma Detection and Management

Mark R. Middleton has published extensively in several academic venues. The most frequent publication outlets are:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Regular and Young Investigator Award Abstracts
  • bioRxiv (Cold Spring Harbor Laboratory)
  • European Journal of Cancer

Their recent papers include:

  • "Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial" (2020, The Lancet Oncology)
  • "Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma" (2020, Nature Medicine)
  • "European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment" (2020, European Journal of Cancer)
  • "Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma" (2020, Clinical Cancer Research)
  • "European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention" (2020, European Journal of Cancer)

Frequent collaborators in research include:

  • Joseph J. Sacco
  • Benjamin P. Fairfax
  • Pippa Corrie
  • Nicholas Coupe
  • Anna Olsson-Brown

Best Publications

  • Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

    Keith T. Flaherty;Caroline Robert;Peter Hersey;Paul Nathan

  • Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

    Jeffrey Weber;Mario Mandala;Michele Del Vecchio;Helen J. Gogas

  • Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

    Mark R Middleton;J J Grob;N Aaronson;G Fierlbeck

  • The safety and feasibility of extracorporeal high-intensity focused ultrasound (HIFU) for the treatment of liver and kidney tumours in a Western population

    R O Illing;J E Kennedy;F Wu;G R ter Haar

  • Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.

    John P. Neoptolemos;Malcolm J. Moore;Trevor F. Cox;Juan W. Valle

  • High-intensity focused ultrasound for the treatment of liver tumours.

    J.E. Kennedy;F. Wu;G.R. ter Haar;F.V. Gleeson

  • Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline

    Alexander Stratigos;Claus Garbe;Celeste Lebbe;Josep Malvehy

  • Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

    Ruth Plummer;Christopher Jones;Mark Middleton;Richard Wilson

  • Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2012

    Claus Garbe;Ketty Peris;Axel Hauschild;Philippe Saiag

  • Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.

    Paolo A. Ascierto;Michele Del Vecchio;Mario Mandalá;Helen Gogas

  • Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study

    Juan W. Valle;Daniel Palmer;Richard Jackson;Trevor Cox

  • Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

    Robert H. I. Andtbacka;Frances Collichio;Kevin J. Harrington;Mark R. Middleton

  • Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline

    Celeste Lebbe;Jürgen C Becker;Jean-Jacques Grob;Josep Malvehy

  • Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A.

    Carmela De Santo;Ramon Arscott;Sarah Booth;Ioannis Karydis

  • Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial

    William Greenhalf;Paula Ghaneh;John P. Neoptolemos;Daniel H. Palmer

  • Adjuvant Interferon in High-Risk Melanoma: The AIM HIGH Study—United Kingdom Coordinating Committee on Cancer Research Randomized Study of Adjuvant Low-Dose Extended-Duration Interferon Alfa-2a in High-Risk Resected Malignant Melanoma

    Barry W Hancock;Keith Wheatley;S Harris;Natalie J Ives

  • The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer

    Srinivasan Madhusudan;Mark R. Middleton

  • European interdisciplinary guideline on invasive squamous cell carcinoma of the skin : Part 2. Treatment

    Alexander J Stratigos;Claus Garbe;Clio Dessinioti;Celeste Lebbe

  • Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma.

    Benjamin P. Fairfax;Chelsea A. Taylor;Robert A. Watson;Isar Nassiri

  • Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma

    John M. Kirkwood;Lars Bastholt;Caroline Robert;Jeffrey A Sosman

Frequent Co-Authors

Paul Lorigan
Paul Lorigan University of Manchester
Geoffrey P. Margison
Geoffrey P. Margison University of Manchester
Michele Maio
Michele Maio University of Siena
Michael L. Dustin
Michael L. Dustin University of Oxford
Helen Gogas
Helen Gogas National and Kapodistrian University of Athens
James Larkin
James Larkin Royal Marsden NHS Foundation Trust
adrian l harris
adrian l harris University of Oxford
Omid Hamid
Omid Hamid Cedars-Sinai Medical Center
Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
David J. Kerr
David J. Kerr University of Oxford

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative and supplemental pathways to traditional medical education can open new doors in healthcare. Many aspiring professionals seek flexible options, such as the dnp program without clinical hours—ideal for those balancing work or familial commitments while aiming to advance to doctoral-level nursing leadership.

For students wanting to enter the workforce rapidly, choosing a 6 month lpn program provides a fast track to practical nursing positions, allowing graduates to gain hands-on experience sooner.

Those interested in mental health and advanced practice nursing may consider psych np online programs. These specialized Master’s degrees prepare nurses for high-demand roles in psychiatric and mental health services, often with accelerated or flexible schedules.

Additionally, if your passion lies in the administrative or management side of healthcare, a focus on the cheapest online health science degree can provide a cost-effective route to impactful careers in healthcare leadership and policy.

Best Scientists Citing Mark R. Middleton

Trending Scientists

Recently Published Articles